Please Wait.....
Report
Latin America Hemoglobinopathies Market Report and Forecast 2024-2032
Market Report I 2024-06-26 I 140 Pages I EMR Inc.
Latin America Hemoglobinopathies Market Report and Forecast 2024-2032
Latin America Hemoglobinopathies Market Size
The global hemoglobinopathies market valued at USD 6.9 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032. The market is poised to secure a market value of USD 15.9 billion by 2032, driven by the rising incidence of thalassemia and sickle cell anemia across the region.
Latin America Hemoglobinopathies Market Outlook
- The rising incidence of sickle cell disease (SCD) and thalassemia, which are amongst the most prevalent hemoglobinopathies boosting the market demand in Latin American region.
- In November 2023, the IAEA trained over 30 Latin American and Caribbean health experts in blood irradiation, enhancing regional safety, standardization, and collaboration in medical practices. Such initiatives to drive awareness amongst healthcare providers is one of the significant Latin America hemoglobinopathies market trends.
- In December 2023, University of Maryland School of Medicine researchers discussed new sickle cell disease treatments at a symposium in Rio De Janeiro, Brazil, addressing the disease affecting 20 million globally. The establishment of such events underscores the emphasis on managing and treating hemoglobinopathies effectively.
Latin America Hemoglobinopathies Market Analysis
Hemoglobinopathies are a group of inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies. Sickle cell disease (SCD) is a group of hereditary chronic diseases that has significantly reduced the quality of life. The prevalence of HbS, (sickle hemoglobin) is quite common in Colombia, predominantly affecting males. The ancestry has influenced the distribution of hemoglobinopathies in different geographical regions of Colombia, driving the increasing number of cases in the market. Thalassemia is one of the common hemoglobinopathies as well.
The Latin America hemoglobinopathies market growth is expected to be driven by the increasing focus of researchers on developing effective treatments for hemoglobinopathies such as thalassemia and sickle cell disease. Researchers are more inclined toward finding and delivering the best technique, technology, and treatment for the management of chronic disease, propelling the market demand. For instance, in December 2023, University of Maryland School of Medicine (UMSOM) dean joined prominent scientists and government health officials at a symposium in Rio De Janeiro, Brazil, to discuss new treatments for sickle cell disease (SCD). The symposium highlighted the developments undergoing in a randomized multicenter clinical trial for Sickle Cell Disease and CardiovAscular Risk-Red Cell Exchange Trial (SCD-CARRE), conducted across 22 sites in Brazil, France, and the United States. Such events are projected to boost the Latin America hemoglobinopathies market share as conducting it among the diverse population of Brazil will not only make the trial challenging but rather contribute to increased efficiency and accuracy, helpful in becoming a standard treatment option.
The market is poised to be driven by the strategic initiatives of organisations to train health practitioners on safe blood irradiation practices. For instance, in November 2023, the International Atomic Energy Agency (IAEA) organized a regional training course on the safe delivery of blood irradiation services for health practitioners in Latin America and the Caribbean. 30+ experts from domains such as hematology, biochemistry, physics, quality assurance, and radiation technology were gathered to update and share their knowledge, and best practices, and learn from each other's experiences. The emphasis on delivering immediate and quality care to the patients is one of the major Latin America hemoglobinopathies market trends expected to boost the market value positively in the forecast period.
Patients suffering from hemoglobinopathies like thalassemia and sickle cell disease require frequent blood transfusions. This training ensures that health practitioners are well-trained in delivering safer blood transfusions. Improved safety and efficacy of transfusions directly enhance patient outcomes and could lead to increased trust and reliance on transfusion services. This is likely to impact the market positively by improving the quality of care and increasing awareness about the necessary measures required to be taken during the process.
Latin America Hemoglobinopathies Market Segmentation??
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
Market Breakup by Treatment
Stem-Cell Transplantation
Blood Transfusions
Analgesics
Antibiotics
Ace Inhibitors
Hydroxyurea
Monoclonal Antibody Medication
Others
Market Breakup by Test Type
Routine Red Blood Cell (RBC) Count
Genetic Testing
Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
Hemoglobin Isoelectric Focusing (Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin Solubility Test
Market Breakup by End User
Hospitals and Clinics
Diagnostics Laboratories
Others
Market Breakup by Country
Brazil
Argentina
Mexico
Others
Latin America Hemoglobinopathies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:?
- Abbott
- Alnylam Pharmaceuticals, Inc.
- Biogen
- Bristol-Myers Squibb Company
- Danaher
- Emmaus Medical, Inc.
- F. Hoffmann-La Roche Ltd
- Gamida Cell
- Global Blood Therapeutics, Inc.
- Novartis
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.?
FAQs
- What was the Latin America hemoglobinopathies market forecast outlook for 2024-2032?
The Latin America hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.
- What are the major factors aiding the Latin America hemoglobinopathies market demand? The increasing number of research activities to find new treatments for sickle cell disease and thalassemia are driving the market demand.
- What are the major Latin America hemoglobinopathies market trends??
Organisations like the IAEA conducting training sessions for healthcare practitioners to learn the best practices from experts is a major trend influencing market growth.
- What are the types of hemoglobinopathies?
Different types of hemoglobinopathies in the market are thalassemia, sickle cell disease and other Hb variant diseases.
- What treatments for hemoglobinopathies are available in the market?
Treatments available for hemoglobinopathies include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, monoclonal antibody medication, and others.
- What kind of tests are performed for hemoglobinopathies?
Type of tests includes routine red blood cell (RBC) Count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
- Who are the end users in the market?
End users in the market include hospitals and clinics, and diagnostic laboratories among others.
- What is the market segmentation by country??
The market segmentation by countries include Brazil, Argentina, Mexico, and others.
- Who are the key players in the Latin America Hemoglobinopathies market?
The key players in the market are Abbott, Alnylam Pharmaceuticals, Inc., Biogen, Bristol-Myers Squibb Company, Danaher, Emmaus Medical, Inc., F. Hoffmann-La Roche Ltd, Gamida Cell, Global Blood Therapeutics, Inc., and Novartis.
Meta description
The Latin America hemoglobinopathies market size is poised for growth, driven by the expansion of the global market, which was valued at USD 6.9 billion in 2023 and is projected to grow at a CAGR of 9.7% during the forecast period of 2024-2032.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Latin America Hemoglobinopathies Market Overview
3.1 Latin America Hemoglobinopathies Market Historical Value (2017-2023)
3.2 Latin America Hemoglobinopathies Market Forecast Value (2024-2032)
4 Latin America Hemoglobinopathies Market Landscape*
4.1 Latin America Hemoglobinopathies: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Latin America Hemoglobinopathies: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Treatment
5 Latin America Hemoglobinopathies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Hemoglobinopathies Market Segmentation (2017-2032)
6.1 Latin America Hemoglobinopathies Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Thalassemia
6.1.3 Sickle Cell Disease
6.1.4 Other Hb Variants Diseases
6.2 Latin America Hemoglobinopathies Market (2017-2032) by Treatment
6.2.1 Market Overview
6.2.2 Stem-Cell Transplantation
6.2.3 Blood Transfusions
6.2.4 Analgesics
6.2.5 Antibiotics
6.2.6 Ace Inhibitors
6.2.7 Hydroxyurea
6.2.8 Monoclonal Antibody Medication
6.2.9 Others
6.3 Latin America Hemoglobinopathies Market (2017-2032) by Test Type
6.3.1 Market Overview
6.3.2 Routine Red Blood Cell (RBC) Count
6.3.3 Genetic Testing
6.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
6.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
6.3.6 Hemoglobin Electrophoresis (Hb ELP)
6.3.7 Hemoglobin Solubility Test
6.4 Latin America Hemoglobinopathies Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Diagnostics Laboratories
6.4.4 Others
6.5 Latin America Hemoglobinopathies Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Others
7 Brazil Hemoglobinopathies Market (2017-2032)
7.1 Brazil Hemoglobinopathies Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Thalassemia
7.1.3 Sickle Cell Disease
7.1.4 Other Hb Variants Diseases
7.2 Brazil Hemoglobinopathies Market (2017-2032) by Treatment
7.2.1 Market Overview
7.2.2 Stem-Cell Transplantation
7.2.3 Blood Transfusions
7.2.4 Analgesics
7.2.5 Antibiotics
7.2.6 Ace Inhibitors
7.2.7 Hydroxyurea
7.2.8 Monoclonal Antibody Medication
7.2.9 Others
7.3 Brazil Hemoglobinopathies Market (2017-2032) by Test Type
7.3.1 Market Overview
7.3.2 Routine Red Blood Cell (RBC) Count
7.3.3 Genetic Testing
7.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
7.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
7.3.6 Hemoglobin Electrophoresis (Hb ELP)
7.3.7 Hemoglobin Solubility Test
7.4 Brazil Hemoglobinopathies Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals and Clinics
7.4.3 Diagnostics Laboratories
7.4.4 Others
8 Argentina Hemoglobinopathies Market (2017-2032)
8.1 Argentina Hemoglobinopathies Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Thalassemia
8.1.3 Sickle Cell Disease
8.1.4 Other Hb Variants Diseases
8.2 Argentina Hemoglobinopathies Market (2017-2032) by Treatment
8.2.1 Market Overview
8.2.2 Stem-Cell Transplantation
8.2.3 Blood Transfusions
8.2.4 Analgesics
8.2.5 Antibiotics
8.2.6 Ace Inhibitors
8.2.7 Hydroxyurea
8.2.8 Monoclonal Antibody Medication
8.2.9 Others
8.3 Argentina Hemoglobinopathies Market (2017-2032) by Test Type
8.3.1 Market Overview
8.3.2 Routine Red Blood Cell (RBC) Count
8.3.3 Genetic Testing
8.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
8.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
8.3.6 Hemoglobin Electrophoresis (Hb ELP)
8.3.7 Hemoglobin Solubility Test
8.4 Argentina Hemoglobinopathies Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals and Clinics
8.4.3 Diagnostics Laboratories
8.4.4 Others
9 Mexico Hemoglobinopathies Market (2017-2032)
9.1 Mexico Hemoglobinopathies Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Thalassemia
9.1.3 Sickle Cell Disease
9.1.4 Other Hb Variants Diseases
9.2 Mexico Hemoglobinopathies Market (2017-2032) by Treatment
9.2.1 Market Overview
9.2.2 Stem-Cell Transplantation
9.2.3 Blood Transfusions
9.2.4 Analgesics
9.2.5 Antibiotics
9.2.6 Ace Inhibitors
9.2.7 Hydroxyurea
9.2.8 Monoclonal Antibody Medication
9.2.9 Others
9.3 Mexico Hemoglobinopathies Market (2017-2032) by Test Type
9.3.1 Market Overview
9.3.2 Routine Red Blood Cell (RBC) Count
9.3.3 Genetic Testing
9.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
9.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
9.3.6 Hemoglobin Electrophoresis (Hb ELP)
9.3.7 Hemoglobin Solubility Test
9.4 Mexico Hemoglobinopathies Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals and Clinics
9.4.3 Diagnostics Laboratories
9.4.4 Others
10 Regulatory Framework
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication Year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by Year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by Departments
12.7 Analysis by Recipient Organization
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 Abbott
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Alnylam Pharmaceuticals, Inc.
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Biogen
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Bristol-Myers Squibb Company
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Danaher
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Emmaus Medical, Inc.
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 F. Hoffmann-La Roche Ltd
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Gamida Cell
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Global Blood Therapeutics, Inc.
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Novartis
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Latin America Hemoglobinopathies Market - Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security